In last trading session, Zentalis Pharmaceuticals Inc. (NASDAQ:ZNTL) saw 0.37 million shares changing hands with its beta currently measuring 0. Company’s recent per share price level of $67.54 trading at $2.2 or 3.37% at ring of the bell on the day assigns it a market valuation of $3.19B. That closing price of ZNTL’s stock is at a discount of -29.09% from its 52-week high price of $87.19 and is indicating a premium of 48.95% from its 52-week low price of $34.48. Taking a look at company’s average trading volume of 247.72K if we extend that period to 3-months.
For Zentalis Pharmaceuticals Inc. (ZNTL), analysts’ consensus is at an average recommendation of a Buy while assigning it a mean rating of 1.30. Splitting up the data highlights that, out of 9 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 9 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$1.32 in the current quarter.
Zentalis Pharmaceuticals Inc. (NASDAQ:ZNTL) trade information
Upright in the green during last session for gaining 3.37%, in the last five days ZNTL remained trading in the red while hitting it’s week-highest on Tuesday, 01/11/22 when the stock touched $67.54 price level, adding 8.63% to its value on the day. Zentalis Pharmaceuticals Inc.’s shares saw a change of -19.65% in year-to-date performance and have moved -3.20% in past 5-day. Zentalis Pharmaceuticals Inc. (NASDAQ:ZNTL) showed a performance of -14.81% in past 30-days.
Wall Street analysts have assigned a consensus price target of $100.22 to the stock, which implies a rise of 32.61% to its current value. Analysts have been projecting $88.00 as a low price target for the stock while placing it at a high target of $120.00. It follows that stock’s current price would drop -77.67% in reaching the projected high whereas dropping to the targeted low would mean a loss of -30.29% for stock’s current value.
Zentalis Pharmaceuticals Inc. (ZNTL) estimates and forecasts
Statistics highlight that Zentalis Pharmaceuticals Inc. is scoring comparatively lower than the scores of other players of the relevant industry. The company added 40.10% of value to its shares in past 6 months, showing an annual growth rate of -0.72% while that of industry is 7.90. Apart from that, the company came lowering its revenue forecast for fiscal year 2022. The company is estimating its revenue growth to decrease by -30.70% in the current quarter and calculating -20.20% decrease in the next quarter.
Zentalis Pharmaceuticals Inc. is more likely to be releasing its next quarterly report between March 23 and March 28 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
Zentalis Pharmaceuticals Inc. (NASDAQ:ZNTL)’s Major holders
Insiders are in possession of 8.07% of company’s total shares while institution are holding 92.59 percent of that, with stock having share float percentage of 100.72%. Investors also watch the number of corporate investors in a company very closely, which is 92.59% institutions for Zentalis Pharmaceuticals Inc. that are currently holding shares of the company. FMR, LLC is the top institutional holder at ZNTL for having 6.76 million shares of worth $450.35 million. And as of Sep 29, 2021, it was holding 14.92% of the company’s outstanding shares.
The second largest institutional holder is Matrix Capital Management, which was holding about 4.35 million shares on Sep 29, 2021. The number of shares represents firm’s hold over 9.60% of outstanding shares, having a total worth of $289.84 million.
On the other hand, Fidelity Select Portfolios – Health Care and Price (T.Rowe) New Horizons Fund are the top two Mutual Funds which own company’s shares. As of Oct 30, 2021, the former fund manager was holding 1.2 million shares of worth $96.53 million or 2.65% of the total outstanding shares. The later fund manager was in possession of 1.17 million shares on Sep 29, 2021, making its stake of worth around $78.03 million in the company or a holder of 2.58% of company’s stock.